Hematology Oncology Board Review
HemeOncBuddy is a free study hub for hematology and oncology fellows preparing for the hematology, medical oncology and combined boards, and for day-to-day fellowship learning. Start with a disease-site note, check the treatment algorithm, then open the trials behind each recommendation and test yourself.
Board review notes by subspecialty
Benign Hematology 32 notes
- Anemia
- Anemia of chronic disease (anemia of inflammation)
- Antiphospholipid Syndrome (APS/APLS)
- Autoimmune hemolytic anemia (AIHA)
- B12 and folate deficiency
- Disorders of fibrinolysis
- Disseminated Intravascular Coagulation (DIC)
- Eosinophilia
- Hemoglobinopathies
- Hemolytic anemias
- Hemophagocytic lymphohistiocytosis (HLH)
- Hemophilia
- Hemostasis
- Hereditary hemolytic anemias
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Hypercoagulable states
- Immune thrombocytopenia (ITP)
- Iron deficiency anemia
- Iron overload (hemochromatosis)
- Laboratory Techniques
- Neutrophil disorders
- Platelet Disorders
- Porphyrias
- Pregnancy and hematology
- Rare Bleeding Disorders
- Sickle Cell Disease
- Sideroblastic anemia
- Thalassemias
- Thrombophilias and VTE management
- Thrombotic microangiopathies (TTP, HUS) and PNH
- Transfusion Medicine
- Von Willebrand Disease (vWD)
Malignant Hematology 44 notes
- Acute graft-versus-host disease (GVHD)
- Acute lymphoblastic leukemia (ALL)
- Acute Promyelocytic Leukemia (APL)
- AL Amyloidosis
- Allogeneic stem cell transplantation (allo-HSCT)
- AML (Part 1): Biology, Diagnosis, Classification and Risk
- AML (Part 2): Treatment, APL, Relapse and Special Populations
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Bone marrow failure syndromes
- Burkitt lymphoma
- Castleman Disease
- Chronic graft-versus-host disease (GVHD)
- Chronic lymphocytic leukemia (CLL/SLL)
- Chronic myeloid leukemia (CML)
- Chronic Myelomonocytic Leukemia (CMML)
- CNL, atypical CML, and MDS/MPN overlap neoplasms
- Diffuse large B-cell lymphoma (DLBCL)
- Essential thrombocythemia (ET)
- FDA hematology approvals 2022 to 2026
- Follicular lymphoma (FL)
- Gray zone lymphoma and aggressive B-cell lymphomas
- Hematologic malignancies: high-yield review
- Histiocytic & Dendritic Cell Disorders
- Hodgkin lymphoma
- Hypereosinophilic Syndrome (HES)
- Immunophenotyping and stains in hematologic malignancies
- Lymphoma overview: classification, staging, and prognosis
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- MPN and MDS summary
- Multiple myeloma, MGUS, and smoldering myeloma
- Myelodysplastic syndromes (MDS)
- Myeloproliferative neoplasms (MPNs)
- POEMS Syndrome
- Polycythemia vera (PV)
- Post-transplant lymphoproliferative disorder (PTLD)
- Primary CNS lymphoma (PCNSL)
- Primary mediastinal B-cell lymphoma (PMBCL)
- Primary myelofibrosis (PMF)
- Rare Polycythemias (Chuvash, PFCP, TEMPI)
- Solitary plasmacytoma
- Systemic Mastocytosis
- T-cell and NK-cell lymphomas
- Waldenström macroglobulinemia (WM)
Medical Oncology 53 notes
- Adrenal tumors
- Anal cancer
- Biliary Cancers
- Bladder Cancer
- Bone Sarcomas
- Brain and CNS tumors
- Breast Cancer (Part 1): Risk, Genetics, Screening, Diagnosis and Staging
- Breast Cancer (Part 2): DCIS, Early-Stage and Metastatic Treatment
- Cancer epidemiology, screening, and prevention
- Cancer in Older Adults
- Cancer of Unknown Primary (CUP)
- CAR-T and Engager Toxicity
- Cervical cancer
- Chemotherapy-induced nausea and vomiting (CINV)
- Clinical trials
- Colorectal cancer
- Endometrial cancer
- Esophageal and gastric cancer
- Gastrointestinal stromal tumor (GIST)
- Genetic Testing For Hereditary Cancer Syndromes
- Growth Factors
- Growth factors in cancer care: G-CSF, ESAs, and TPO-RAs
- Gynecologic cancers
- Head & Neck Cancer (Part 1): Biology, Workup and Staging
- Head & Neck Cancer (Part 2): Treatment, NPC, CUP and Recurrent Disease
- Hepatocellular carcinoma (HCC)
- Immune Checkpoint Inhibitor Toxicity (irAEs)
- Infections in Cancer Patients
- Melanoma
- Mesothelioma
- Molecular Biology
- Neuroendocrine tumors (NETs)
- Non-cutaneous melanoma
- NSCLC (Part 1): Biology, Screening, Staging, Early-Stage and Stage III
- NSCLC (Part 2): Stage IV, Targeted and Systemic Therapy
- Ovarian cancer
- Pain and symptoms management
- Pancreatic cancer
- Penile cancer
- Prostate cancer
- Rectal cancer
- Renal cell carcinoma (RCC)
- Salivary gland tumors
- Sarcomas
- Small cell lung cancer (SCLC)
- Soft tissue sarcomas
- Supportive care
- Testicular Cancer
- Thymoma
- Thyroid cancers
- Tumor immunology and immunotherapy
- Uterine sarcomas
- Vaginal cancer
Pharmacology 17 notes
- ALK inhibitors
- Alkylating agents
- Antibody-drug conjugates (ADCs)
- Anticoagulants
- Antimetabolites
- Antimicrotubular agents
- Antitumor antibiotics
- BCR::ABL1 tyrosine kinase inhibitors
- BRAF and MEK inhibitors
- CAR T-cell and other cellular therapies
- Chemotherapy agents: mechanisms and toxicities
- Clinical Pharmacology
- EGFR inhibitors
- HER2-targeted therapies
- Multikinase Inhibitors
- Topoisomerase inhibitors
- VEGF inhibitors
Frequently asked questions
What is on HemeOncBuddy for hematology oncology board review?
Disease-site notes (146 so far) that cover malignant hematology, benign hematology, medical oncology and pharmacology; summaries of landmark trials; treatment algorithms; flashcards; and a board-style question bank. Everything is free and works without an account.
How should I use the notes for the ABIM hematology or medical oncology boards?
Read a note for the framework, check the treatment algorithm for the decision points, open the trial summaries behind each recommendation, then test yourself with flashcards and the question bank. Notes also have an audio lecture you can play while commuting.
Is the content reviewed?
Every note was checked against primary sources and current labels, and then re-checked by a second independent review pass. HemeOncBuddy is a study aid: confirm against current guidelines and labeling before clinical decisions.
Who runs HemeOncBuddy?
HemeOncBuddy was built by Veli Bakalov, MD, a medical oncologist at MD Anderson Cancer Center at Cooper, as a free resource for hematology and oncology fellows.